Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Dapagliflozin in Acute Decompensated Heart Failure
NCT05776043Phase 3Recruiting
- Sponsor
- Medical University of Warsaw
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin and dapagliflozin in acute decompensated heart failure (ADHF), sponsored by Medical University of Warsaw. Started Mar 2022; status: recruiting.
02
Drugs
empagliflozindapagliflozin
03
Conditions
acute decompensated heart failure (ADHF)
Beyond the preview
Go deeper on NCT05776043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776043.